FDA And European Medicines Agency Accept Regulatory Submissions For Review Of Dacomitinib - Drug Discovery and Development Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma Oncology Neurological Disease Infectious Disease Video features Pharma 50 2022 Pharma 50 2021 Pharma 50 FDA And European Medicines Agency Accept Regulatory Submissions For Review Of Dacomitinib By Pfizer Inc. | April 5, 2018 Pfizer Inc. announced that the FDA accepted the company’s New Drug Application and granted priority review for dacomitinib, a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The European Agency has also accepted the Marketing Authorization Application for dacomitinib for the same indication. The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in September 2018. “While significant progress has been made in the treatment of patients with non-small cell lung cancers harboring EGFR-activating mutations, it remains a challenging disease and new treatment options are needed,” said Mace Rothenberg, M.D., chief development officer, Oncology, Pfizer Global Product Development. “In the pivotal clinical trial that supports these applications, dacomitinib showed clinically meaningful improvement in progression-free survival over gefitinib, one of the first EGFR-targeted therapies to demonstrate activity in this disease. These filing acceptances are an important step toward increasing treatment options for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.” Dacomitinib is the second investigational Pfizer lung cancer medicine to receive regulatory acceptance within two months, reinforcing Pfizer’s commitment to patients with NSCLC where there continues to be a significant unmet need. The submissions are based on results from the Phase 3 ARCHER 1050 study, a global head-to-head trial investigating dacomitinib (n=227) compared to gefitinib (n=225) that showed dacomitinib may offer a clinically meaningful improvement over gefitinib. Patients that received dacomitinib in the study experienced a median progression-free survival (PFS) of 14.7 months compared with 9.2 months in patients treated with gefitinib, as measured by Blinded Independent Central Review (BICR). This difference represented a 41 percent reduction in the risk of disease progression or death for patients treated with dacomitinib compared with gefitinib (HR = 0.59 [95 percent CI: 0.47,0.74], p <0.0001) as a first-line treatment in locally advanced or metastatic NSCLC with EGFR-activating mutations. The adverse events (AEs) observed with dacomitinib in the study were consistent with findings from previous trials. The most common AEs were diarrhea (87 percent), nail changes (62 percent), rash/dermatitis acneiform (49 percent), and mouth sores (44 percent). The most common Grade three AEs with dacomitinib were rash (14 percent) and diarrhea (eight percent). Grade four AEs occurred in two percent of dacomitinib-treated patients. There was one case of Grade five diarrhea and one case of Grade five liver disease. The discontinuation rate due to treatment-related AEs for dacomitinib was 10 percent compared to seven percent for gefitinib. The ARCHER 1050 results were published in Lancet Oncology, shared as an oral late-breaker presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting and featured in the ASCO press program. A final assessment of overall survival from ARCHER 1050 will be presented at a medical meeting later this year. (Source: Pfizer Inc.) Filed Under: Drug Discovery Related Articles Read More > FDA releases draft guidance to protect children in clinical trials MindMed announces Phase 1 study of MDMA-like substances Women in Pharma: AstraZeneca executive vice president Susan Galbraith has helped develop seven blockbuster drugs How effective is ketamine for depression? Need Drug Discovery news in a minute? We Deliver! Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today. Connect with Drug Discovery & Development Drug Discovery and Development MassDevice DeviceTalks Medical Design & Outsourcing Medical Tubing + Extrusion Medtech100 Index Medical Design Sourcing Subscribe to our Free E-Newsletter Contact Us About Us Advertise With Us R&D World Drug Delivery Business News Pharmaceutical Processing World Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media Privacy Policy | Advertising | About Us Search Drug Discovery & Development Home Drug Discovery and Development Drug Discovery Women in Pharma Oncology Neurological Disease Infectious Disease Video features Pharma 50 2022 Pharma 50 2021 Pharma 50